Michele Senni

8.0k total citations · 1 hit paper
16 papers, 126 citations indexed

About

Michele Senni is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michele Senni has authored 16 papers receiving a total of 126 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cardiology and Cardiovascular Medicine, 9 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michele Senni's work include Heart Failure Treatment and Management (12 papers), Hormonal Regulation and Hypertension (6 papers) and Cardiovascular Function and Risk Factors (6 papers). Michele Senni is often cited by papers focused on Heart Failure Treatment and Management (12 papers), Hormonal Regulation and Hypertension (6 papers) and Cardiovascular Function and Risk Factors (6 papers). Michele Senni collaborates with scholars based in Italy, United Kingdom and United States. Michele Senni's co-authors include Jan Bělohlávek, Adele Noè, Rolf Wachter, Domingo A. Pascual‐Figal, Dmytro Butylin, Sanjiv J Shah, Scott D Solomon, Akshay S. Desai, H. Schwende and Brian Claggett and has published in prestigious journals such as The Lancet, Journal of the American College of Cardiology and Journal of the American Society of Nephrology.

In The Last Decade

Michele Senni

12 papers receiving 124 citations

Hit Papers

Mineralocorticoid receptor antagonists in heart failure: ... 2024 2026 2024 10 20 30 40 50
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
    2024 52 citations Pardeep S. Jhund, Atefeh Talebi et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michele Senni Italy 5 104 49 36 8 7 16 126
Peter Szecsödy Switzerland 5 68 0.7× 16 0.3× 33 0.9× 6 0.8× 10 1.4× 6 88
Glenn S. Hamroff United States 3 194 1.9× 49 1.0× 26 0.7× 12 1.5× 8 1.1× 3 203
Pierre Ollitrault France 7 125 1.2× 31 0.6× 13 0.4× 8 1.0× 4 0.6× 29 154
Juan Luis Arango Argentina 2 106 1.0× 38 0.8× 17 0.5× 8 1.0× 2 0.3× 3 118
Akshay S. Desai United States 4 60 0.6× 32 0.7× 29 0.8× 6 0.8× 11 1.6× 11 79
Alan Charney United States 4 135 1.3× 41 0.8× 36 1.0× 7 0.9× 5 0.7× 7 156
Jonathan H. Ward United States 10 283 2.7× 67 1.4× 56 1.6× 13 1.6× 5 0.7× 30 311
Maria G. Crespo‐Leiro Spain 3 68 0.7× 12 0.2× 23 0.6× 6 0.8× 4 0.6× 3 78
G. Cartoni Italy 5 160 1.5× 42 0.9× 43 1.2× 11 1.4× 9 1.3× 6 194
Paula Campora Italy 3 67 0.6× 14 0.3× 23 0.6× 6 0.8× 6 0.9× 3 85

Countries citing papers authored by Michele Senni

Since Specialization
Citations

This map shows the geographic impact of Michele Senni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Senni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Senni more than expected).

Fields of papers citing papers by Michele Senni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele Senni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Senni. The network helps show where Michele Senni may publish in the future.

Co-authorship network of co-authors of Michele Senni

This figure shows the co-authorship network connecting the top 25 collaborators of Michele Senni. A scholar is included among the top collaborators of Michele Senni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Senni. Michele Senni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Butt, Jawad H., Pardeep S. Jhund, Alasdair Henderson, et al.. (2025). Finerenone, Glycaemic Status, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. European Journal of Heart Failure. 27(7). 1326–1341.
2.
Butt, Jawad H., Pardeep S. Jhund, Alasdair Henderson, et al.. (2025). Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial. European Journal of Heart Failure. 27(8). 1444–1458. 1 indexed citations
3.
Ferreira, João Pedro, Brian Claggett, Ian J. Kulac, et al.. (2025). Interplay of Serum Potassium and Kidney Function with Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Findings from FINEARTS-HF. European Journal of Heart Failure. 27(11). 2422–2432.
4.
Ostrominski, John W., Brian Claggett, Akshay S. Desai, et al.. (2025). EFFICACY AND SAFETY OF FINERENONE ACROSS THE SPECTRUM OF KIDNEY RISK IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION. Journal of the American College of Cardiology. 85(12). 1167–1167.
5.
Butt, Jawad H., Alasdair Henderson, Pardeep S. Jhund, et al.. (2025). FINERENONE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION: AN ANALYSIS OF FINEARTS-HF. Journal of the American College of Cardiology. 85(12). 1200–1200.
6.
Docherty, Kieran F., Rudolf A. de Boer, Jersey Chen, et al.. (2024). Wearable Accelerometer-Derived Measures of Physical Activity in Heart Failure: Insights From the DETERMINE trials. Journal of Cardiac Failure. 31(4). 689–703. 1 indexed citations
7.
Jhund, Pardeep S., Atefeh Talebi, Alasdair Henderson, et al.. (2024). Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. The Lancet. 404(10458). 1119–1131. 52 indexed citations breakdown →
8.
Udelson, James E., Howard K. Surks, Jan Bělohlávek, et al.. (2024). A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure. European Heart Journal. 45(Supplement_1). 1 indexed citations
9.
Causland, Finnian R. Mc, Muthiah Vaduganathan, Brian Claggett, et al.. (2024). Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial. Journal of the American Society of Nephrology. 35(10S). 1 indexed citations
10.
Vaduganathan, Muthiah, Brian Claggett, Akshay S. Desai, et al.. (2024). Estimated Long-Term Benefits of Finerenone in Heart Failure. JAMA Cardiology. 10(2). 176–176. 5 indexed citations
11.
Docherty, Kieran F., Rudolf A. de Boer, Martín Cowie, et al.. (2024). Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials. Circulation Heart Failure. 17(10). e012349–e012349. 3 indexed citations
12.
Straburzyńska‐Migaj, Ewa, Michele Senni, Rolf Wachter, et al.. (2023). Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study. Journal of Cardiac Failure. 30(3). 425–435. 4 indexed citations
13.
Witte, Klaus K., Rolf Wachter, Michele Senni, et al.. (2022). Influence of Diabetes on Sacubitril/Valsartan Titration and Clinical Outcomes in Patients Hospitalized for Heart Failure. ESC Heart Failure. 10(1). 80–89. 6 indexed citations
14.
15.
Wachter, Rolf, Domingo A. Pascual‐Figal, Jan Bělohlávek, et al.. (2019). P773Initiation of sacubitril/valsartan and optimisation of evidence-based heart failure therapies after hospitalisation for acute decompensated heart failure: An analysis of the TRANSITION study. European Heart Journal. 40(Supplement_1). 1 indexed citations
16.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter Szecsödy Breakdown of academic impact, for papers by Glenn S. Hamroff Breakdown of academic impact, for papers by Pierre Ollitrault Breakdown of academic impact, for papers by Juan Luis Arango Breakdown of academic impact, for papers by Akshay S. Desai Breakdown of academic impact, for papers by Alan Charney Breakdown of academic impact, for papers by Jonathan H. Ward Breakdown of academic impact, for papers by Maria G. Crespo‐Leiro Breakdown of academic impact, for papers by G. Cartoni Breakdown of academic impact, for papers by Paula Campora
Rankless by CCL
2026